Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Nottingham University Hospital Joins National Trial To Improve Breast Cancer Care For Older Women, UK
http://www.medicalnewstoday.com/articles/126367.php
Over half of breast cancers occur in women aged 65 and over and so in a bid to improve treatments and outcomes for women in this age-group, researchers at Nottingham University Hospitals NHS Trust (NUH) have joined a national research trial which will provide fresh hope for millions of women diagnosed with breast cancer.
3-D Doppler Ultrasound Helps Identify Breast Cancer
http://www.medicalnewstoday.com/articles/126351.php
Three-dimensional (3-D) power Doppler ultrasound helps radiologists distinguish between malignant and benign breast masses, according to a new study being published in the November issue of <i>Radiology</i>.
Peregrine Pharmaceuticals Reports Progress In Its Phase II Trial Of Bavituximab Plus Docetaxel In Patients With Advanced Breast Cancer
http://www.medicalnewstoday.com/articles/126276.php
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria.
----------------------------------------------
** CANCER / ONCOLOGY News **
Argos Therapeutics Publishes Approach To Generating High-Avidity Cytotoxic T Cells With Dendritic Cell-Based Immunotherapy
http://www.medicalnewstoday.com/articles/126435.php
Argos Therapeutics today announced the publication of a paper in the October 15th issue of the <i>Journal of Immunonology</i> demonstrating that the Company's proprietary RNA-electroporated dendritic cells generate high-avidity cytotoxic T cells (CTL) in vitro that are able to destroy cells expressing their target antigens.
Neotropix® Announces Presentation Of Relevant Preclinical Results Of NTX-010 In Pediatric Oncology Models
http://www.medicalnewstoday.com/articles/126426.php
Neotropix®, Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today exciting data from an extensive pediatric preclinical study performed by the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Program on the use of NTX-010 (Seneca Valley Virus-001), a tumor-selective naturally-occurring oncolytic virus.
Boehringer Ingelheim's Promising New Data For Potentially First In Class Plk1 Inhibitor
http://www.medicalnewstoday.com/articles/126362.php
Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, has shown encouraging results in a phase I clinical trial in patients with advanced tumours who have failed to respond to other treatments.
Chronic Inflammation Can Help Nurture Skin Cancer, Study Shows
http://www.medicalnewstoday.com/articles/126357.php
Inflammation, a frontline defense against infection or disease, can help nurture skin cancer, researchers have found.IDO, an enzyme that works like a firefighter to keep inflammation under control, can be commandeered to protect early malignant cells, say Medical College of Georgia researchers studying an animal model of chronic inflammation and skin cancer.
Intimacy And Sexuality After Cancer: Questions Answered And Concerns Addressed
http://www.medicalnewstoday.com/articles/126327.php
Today The Women's Sexual Health Foundation (TWSHF) released an issue of the <i>Women's Sexual Health Foundation Journal</i> devoted entirely to women's sexuality and cancer, a topic the Foundation frequently addresses with healthcare professionals, cancer patients and survivors.
New Way Of Inhibiting The Cell Cycle Shows Promise In Cancer Patients In A Phase I Clinical Trial
http://www.medicalnewstoday.com/articles/126321.php
A new anti-cancer compound that works by blocking a part of the cell's machinery that is crucial for cell division has shown promising results in a phase I clinical trial in patients who have failed to respond to other treatments.
Crossing The Blood-brain Barrier: Scientists Develop New Drug Delivery System For Brain Cancers And Other, Hard-to-treat Diseases Of The CNS
http://www.medicalnewstoday.com/articles/126320.php
Scientists have developed a new drug delivery system that is capable of crossing the blood-brain barrier to reach and kill cancer cells in the brain, according to research presented at the 20th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 22 October).
Bevacizumab Can Be Used To Detect/diagnose Tumours In Animal Models Using PET/CT Imaging: Results Better Than Current 'gold Standard' Method
http://www.medicalnewstoday.com/articles/126319.php
Scientists have developed a new imaging agent that can be used in scanning for tumours, and which gives a much clearer and more precise image than existing methods. The discovery has the potential to revolutionise pre-clinical cancer research and clinical diagnostic practice, and it makes use of compounds that have already been approved for treating patients: the anti-cancer drug bevacizumab (Avastin) and Copper-64, a radioactive copper nuclide, which is approved by the US Food and Drug Administration (FDA) for some clinical trials.
Researchers Identify Pattern Of Gene Expression That Can Predict How Patients With Advanced Bowel Cancer Will Respond To Treatment
http://www.medicalnewstoday.com/articles/126318.php
Research by scientists in France has shown for the first time that identifying patterns of gene expression can be used to predict response to treatment in patients with advanced metastatic colorectal cancer.
Assessing The Quality Of Phase I Clinical Trial Abstracts Submitted To The EORTC-NCI-AACR And ASCO Meetings
http://www.medicalnewstoday.com/articles/126317.php
Researchers have developed a method of assessing the quality of phase I clinical trial abstracts submitted to two different oncology conferences: EORTC-NCI-AACR (ENA) [1] and American Society of Clinical Oncology (ASCO).
Garvan And St Vincent's To Build $100 Million Australian Cancer Centre, Australia
http://www.medicalnewstoday.com/articles/126303.php
The Garvan Institute of Medical Research and St Vincents & Mater Health Sydney will today announce plans to jointly establish a new $100 million Cancer Centre within the St Vincent's Research Precinct.
America's Top Doctors For Cancer Recognizes 20 IU School Of Medicine Physicians
http://www.medicalnewstoday.com/articles/126302.php
Twenty physicians with the Indiana University School of Medicine have been recognized as the best in their field. The 20 are among 25 in Indiana included in the most recent edition of <i>America's Top Doctors for Cancer</i>.
Access Pharmaceuticals Presents ProLindac(TM) Data At The AACR-NCI-EORTC Symposium 2008
http://www.medicalnewstoday.com/articles/126277.php
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that three posters describing significant recent results of the company's proprietary polymer DACH platinum prodrug, ProLindac, in clinical and preclinical studies are being presented this week at a major international oncology conference held in Geneva, Switzerland.
Rare Peptide Segments Are Found Significantly More Often In Proto-Oncoproteins Than Control Proteins: Implications For Immunology And Oncology
http://www.medicalnewstoday.com/articles/126269.php
There is some evidence to suggest that peptide segments that are found rarely or never in the host proteome play a role in the immune response to disease-related proteins, both those derived from microbes and those derived from the host itself.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
New MRI Technique May Identify Cervical Cancer Early
http://www.medicalnewstoday.com/articles/126350.php
Using high-resolution magnetic resonance imaging (MRI) with a special vaginal coil, a technique to measure the movement of water within tissue, researchers may be able to identify cervical cancer in its early stages, according to a new study being published in the November issue of <i>Radiology</i>.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
No news for this category today.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
No news for this category today.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Medivation Announces Presentation Of 24-Week Clinical Data Of MDV3100 In Castration-Resistant Prostate Cancer Patients
http://www.medicalnewstoday.com/articles/126441.php
Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new data from an ongoing Phase 1-2 clinical trial demonstrating that the Company's novel androgen receptor antagonist MDV3100 continues to show promising safety and efficacy results.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment